- Home
- VRAX vs BDRX Comparison
VRAX vs BDRX Comparison
Compare VRAX & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | BDRX |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRAX | BDRX |
|---|---|---|
| Price | $0.66 | $4.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 14.7M | 42.7K |
| Earning Date | 01-01-0001 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,986.00 | N/A |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.35 | $3.58 |
| 52 Week High | $3.20 | $92.00 |
Technical Indicators
Market Signals| Indicator | VRAX | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 47.66 |
| Support Level | $0.39 | $3.60 |
| Resistance Level | $0.43 | $4.80 |
| Average True Range (ATR) | 0.06 | 0.53 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 55.35 | 66.20 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.